Document is current
Any future updates will be listed below
-
Authors
Ortez, Carlos
Branas-Pampillón, María
Fernandez, Joaquín Alejandro
Guillen, Elisa
Terrancle, Ángeles
Maurino, Jorge
Montolio, Marisol
Camacho, Ana
-
Funding
Funding for this research was provided by:
Roche España
- License Information
-
More Information
Article History
Received: 30 December 2025
Accepted: 10 February 2026
First Online: 26 February 2026
Declarations
:
: Carlos Ortez has received speaker fees from Novartis, PTC Therapeutics, Roche, and Sarepta Therapeutics, and is an investigator on clinical trials related to DMD, sponsored by Italfarmaco S.p.A., PTC Therapeutics, Roche, and Sarepta Therapeutics. Ana Camachohas received speaker fees from PTC Therapeutics and is an investigator on clinical trials sponsored by Santhera and Roche. Jorge Maurino, Marian Terrancle, Elisa Guillén, and Maria Brañas Pampillon are employees of Roche Farma Spain. Marisol Montolio has participated in the ePAG Eurordis Advocacy Group and Board of SEMIO (Myology Spanish Society). Joaquín Alejandro Fernandez declared no conflict of interest.
: The study was approved by the Ethics Committee of Hospital Clínico San Carlos, Madrid, Spain and adhered to the Declaration of Helsinki. All participants provided written informed consent.
